Does Medicare Cover Ozempic? GLP-1 Coverage 2026 Guide
Check Your Medicare Coverage →For the first time in Medicare's history, weight loss medications are covered under Part D. The GLP-1 Bridge program launched July 1, 2026 — Wegovy, Zepbound, and Foundayo are now available at $50/month for eligible enrollees, and pharmacies began dispensing on day one. Here is the complete guide to eligibility, enrollment, costs, and what comes after. For the launch-day playbook (first-fill steps, day-1 confusion points), see our Bridge launch report.
Don't qualify under the Bridge tiers?
Take our 2-minute quiz to see affordable GLP-1 programs available right now — from $99/mo, no Medicare paperwork.
Quick compare
Top 3 verified providers
Quick compare
Top 3 verified providers
See if your plan covers GLP-1s
Pick your carrier — we'll show coverage status and match you with providers that accept it.
Coverage summaries based on common plan formularies. Always confirm with your specific plan — call the member services number on your ID card.
Skip the regulatory text
Medicare Eligibility at a Glance
Skip the regulatory text
Medicare Eligibility at a Glance
- •Status: LIVE — launched July 1, 2026; extended through December 31, 2027 (18-month demonstration)
- •Cost: $50/month for Wegovy or Zepbound
- •BMI requirement: ≥30, or ≥27 with weight-related condition (diabetes, hypertension, sleep apnea)
- •You need: Part D PDP or MA-PD enrollment + a prior authorization from your prescriber
- •Prior auth steps: doctor submits BMI, comorbidity diagnosis, and obesity-care plan; plan responds within 7 days
- •Estimated eligible: ~3.4 million Medicare beneficiaries
Key Facts at a Glance
Need coverage now? Affordable cash-pay options
Same active ingredients as Wegovy, Zepbound, and Ozempic — through licensed US telehealth providers, no insurance needed.
Get notified when Medicare coverage changes.
Bridge program tiers, enrollment windows, Part D updates — sent the day they change.
Does Medicare Cover GLP-1 Weight Loss Drugs in 2026?
Yes — live since July 1, 2026. The Medicare GLP-1 Bridge program covers Wegovy, Zepbound, and Foundayo at $50/month for eligible Part D enrollees.
On March 5, 2025, CMS (Centers for Medicare & Medicaid Services) announced the Medicare GLP-1 Bridge program — a historic initiative that will provide Medicare Part D coverage for anti-obesity GLP-1 medications for the first time.1 The program launched on July 1, 2026 and — after CMS extended it — now runs throughDecember 31, 2027; participating pharmacies began dispensing at the $50 copay on day one.
This represents a massive shift in federal health policy. Until now, Medicare has been legally prohibited from covering drugs prescribed solely for weight loss under the Social Security Act. The TREAT Obesity Act, which was included in the bipartisan budget agreement signed in late 2025, amended this prohibition and directed CMS to establish a transitional coverage program.2
The Bridge was first announced as a six-month window, but CMS has since extended it through December 31, 2027— an 18-month demonstration. CMS decided in April 2026 not to launch its companion BALANCE Model in Medicare (BALANCE proceeded only in Medicaid), so the extended Bridge is now Medicare's coverage pathway for anti-obesity GLP-1s.
CMS estimates that approximately 3.4 million Medicare beneficiaries will be eligible for the Bridge program, though actual enrollment will depend on prescriber capacity and patient awareness.3
Why "Bridge"?
CMS calls this a "bridge" because it was meant to connect the old state (no Medicare obesity drug coverage) to a permanent framework. That permanent Medicare framework (the BALANCE Model) was ultimately not adopted, so CMS extended the Bridge itself through December 31, 2027 to keep coverage in place.
How Much Will Medicare GLP-1 Coverage Cost?
Medicare beneficiaries will pay a maximum of $50/month for covered GLP-1 medications under the Bridge program -- a savings of up to 96% compared to the $998-$1,349 retail price.
The headline number is $50 per month — that is the maximum amount a Medicare beneficiary will pay out of pocket for a covered GLP-1 medication under the Bridge program.4
To put that in perspective, these same medications cost $900 to $1,350 per month at retail price without insurance. Even with commercial insurance, many patients pay $150–$300/month after copays and deductibles. The $50 Bridge price represents savings of up to 96%.
Here is how the $50/month pricing works:
- Fixed copayment structure: The $50 monthly maximum applies regardless of which covered medication you take (Wegovy or Zepbound). This is a flat copay, not a percentage-based coinsurance.5
- No deductible applies: The Bridge program copayment is not subject to the Part D deductible. You pay $50 from month one.
- Manufacturer contribution: Both Novo Nordisk (Wegovy) and Eli Lilly (Zepbound) have agreed to provide significant rebates to CMS to make the $50 price point possible. The exact rebate amounts have not been disclosed but are estimated at 60–75% of list price.6
- No impact on catastrophic coverage: Bridge program costs do not count toward the Part D out-of-pocket maximum ($2,000 in 2026 under the Inflation Reduction Act).
Bottom Line on Cost
If you are a Medicare Part D enrollee who meets the clinical criteria, you will pay no more than $50/month for Wegovy or Zepbound through December 31, 2027. That is roughly $900 over the 18-month program for medication that would otherwise cost $16,200–$24,300. The copay also does not count toward your Part D deductible or your annual out-of-pocket maximum ($2,100 in 2026, $2,400 in 2027).
Which GLP-1 Drugs Does Medicare Cover?
The Medicare Bridge program covers two FDA-approved anti-obesity medications: Wegovy (semaglutide by Novo Nordisk) and Zepbound (tirzepatide by Eli Lilly), in both injectable and oral forms.
The Bridge program covers two FDA-approved anti-obesity medications:
Wegovy
semaglutide 2.4mg
- Manufacturer: Novo Nordisk
- Weekly injection
- FDA-approved for obesity (2021)
- Also approved for cardiovascular risk reduction
- Avg. weight loss: 15–17% of body weight
Zepbound
tirzepatide
- Manufacturer: Eli Lilly
- Weekly injection
- FDA-approved for obesity (2023)
- Dual GIP/GLP-1 receptor agonist
- Avg. weight loss: 18–22% of body weight
What Is NOT Covered
The following medications are not included in the Bridge program:
- Ozempic (semaglutide 0.5mg/1mg/2mg) — FDA-approved for type 2 diabetes, not obesity. Medicare already covers Ozempic for its on-label diabetes indication under standard Part D. The Bridge program specifically covers anti-obesity medications.7
- Mounjaro (tirzepatide) — The diabetes-branded version of the same molecule as Zepbound. Like Ozempic, it is already covered for diabetes under Part D.
- Compounded semaglutide or tirzepatide — Only FDA-approved brand-name products are eligible. Compounded versions from 503A or 503B pharmacies are excluded.
- Rybelsus (oral semaglutide) — Currently only FDA-approved for diabetes, not obesity. Not included in the Bridge program.
- Saxenda (liraglutide) — An older GLP-1 obesity medication with less efficacy. Not included in the Bridge program.
Important Distinction
If you currently take Ozempic or Mounjaro for type 2 diabetes, your existing Part D coverage continues unchanged. The Bridge program adds new coverage for obesity medications — it does not replace or modify existing diabetes drug benefits.
Get personalized recommendations
Match with cash-pay programs at Medicare-comparable pricing — 2-minute quiz.
Who Is Eligible for Medicare GLP-1 Coverage?
You are eligible if you are enrolled in Medicare Part D (PDP or MA-PD), have a BMI of 30+ (or 27+ with a weight-related condition), and obtain prior authorization from your prescriber.
To qualify for the Medicare GLP-1 Bridge program, you must meet all of the following criteria:8
1. Medicare Enrollment
You must be actively enrolled in a Medicare Part D prescription drug plan (PDP) or a Medicare Advantage plan with prescription drug coverage (MA-PD) for the 2026 plan year. Original Medicare alone (Parts A and B) does not include drug coverage and is not sufficient.
If you are currently enrolled in a Part D plan, you do not need to switch plans. All Part D PDPs and MA-PDs are required to participate in the Bridge program.9
2. Clinical Criteria (BMI and Diagnosis)
You must have a clinical indication for anti-obesity medication, which generally means:
- BMI of 30 or greater (clinical obesity), OR
- BMI of 27 or greater with at least one weight-related comorbidity (such as type 2 diabetes, hypertension, dyslipidemia, obstructive sleep apnea, or cardiovascular disease)
These are the same FDA-label criteria that apply to Wegovy and Zepbound prescriptions generally. Your prescribing physician will need to document these criteria.
3. Prescriber Requirements
The prescription must come from a qualified healthcare provider — typically a physician (MD/DO), nurse practitioner, or physician assistant authorized to prescribe in your state. CMS has not imposed additional prescriber restrictions beyond standard state scope-of-practice rules.10
Telehealth prescriptions are permitted. If you are already seeing a telehealth GLP-1 provider, they can write a prescription that qualifies for Bridge program coverage, as long as they accept Medicare.
Who Is NOT Eligible
- Beneficiaries enrolled in Original Medicare without Part D
- Individuals under 65 with Medicare due to disability who do not have Part D
- People enrolled in Medicaid but not Medicare (Medicaid has separate rules by state)
- Those who do not meet the BMI clinical criteria
- Beneficiaries in the Medicare Savings Program may have different cost-sharing — check with your plan
How Do You Enroll in the Medicare GLP-1 Bridge Program?
There is no separate enrollment — coverage is automatic through your existing Part D plan, and it's live now. Verify Part D enrollment, schedule a doctor visit, and have your prescriber submit the Bridge prior authorization (5-14 day turnaround on clean submissions).
The good news: there is no separate enrollment process for the Bridge program. If you meet the criteria above, coverage is automatic through your existing Part D plan. Here is what you need to do:
Confirm Your Part D Enrollment
Log in to Medicare.gov or call 1-800-MEDICARE (1-800-633-4227) to verify you are enrolled in a Part D PDP or MA-PD plan for 2026. If you are not enrolled, the next Open Enrollment Period is October 15 – December 7, 2026 for 2027 coverage. However, you may qualify for a Special Enrollment Period.
Schedule an Appointment with Your Doctor
You need a prescription from a Medicare-accepting provider. Schedule an appointment — either in-person or via telehealth — to discuss GLP-1 medication for weight management. Bring documentation of your BMI history and any weight-related conditions.
Get Prior Authorization (If Required)
Most Part D plans will require prior authorization for Wegovy or Zepbound. Your doctor's office will submit this to your plan. CMS has directed plans to use streamlined criteria for Bridge program medications, but processing times may vary. Start this process in May–June 2026 to be ready for July 1.
Fill Your Prescription at a Participating Pharmacy
Once authorized, fill your prescription at any pharmacy in your plan's network. Your copay will be $50 or less per monthly supply. Specialty pharmacies and mail-order pharmacies are both eligible.
Begin Your Dose Titration
Both Wegovy and Zepbound require a dose escalation schedule over several months. Your doctor will start you on the lowest dose and gradually increase. Do not skip the titration — it significantly reduces side effects.
Start the Process Early
Prior authorizations can take 1–4 weeks. Dose titration takes 4–5 months to reach the maintenance dose. If you wait until July 1 to begin, you may not reach full efficacy before the Bridge program ends in December. Start talking to your doctor now so you are ready on day one.
What Are the BMI Requirements and Prior Authorization Steps?
You need a documented BMI of 30+ (or 27+ with a comorbidity like hypertension or sleep apnea), plus prior authorization submitted by your prescribing physician to your Part D plan.
The prior authorization process is where many people get tripped up. Here is what to expect and how to prepare.
What Your Plan Will Review
When your doctor submits a prior authorization, the Part D plan will typically verify:
- Your BMI qualifies (30+ or 27+ with comorbidity)
- The diagnosis is documented in medical records
- The prescriber is a qualified, Medicare-enrolled provider
- The specific medication requested (Wegovy or Zepbound) is on the plan formulary for the Bridge program
CMS Guidance on Streamlined Authorization
CMS issued guidance in its April 2026 final rule directing Part D plans to implement "streamlined prior authorization" for Bridge program medications.11 This means:
- Plans cannot impose step therapy requirements (e.g., requiring you try a cheaper drug first)
- Plans cannot require a minimum number of supervised diet attempts before approval
- Authorization decisions must be made within 72 hours for standard requests and 24 hours for expedited requests
- Initial authorization must cover the full titration and maintenance period through December 31, 2027
If Your Prior Authorization Is Denied
If your plan denies the prior authorization, you have the right to appeal. The appeals process is:
- Coverage determination redetermination — Request a review by your plan (7 days for standard, 72 hours for expedited)
- Independent Review Entity (IRE) — If the plan upholds the denial, an independent body reviews the case
- Administrative Law Judge (ALJ) hearing — For amounts over $190 (2026 threshold)
CMS has indicated that denial rates for Bridge program medications should be low given the streamlined criteria, but early months may see processing delays as plans build out their systems.12
The BALANCE Model and Why the Bridge Was Extended
When the Bridge was first announced, CMS framed it as a short on-ramp to the BALANCE Model — a Center for Medicare and Medicaid Innovation (CMMI) pilot pairing value-based manufacturer contracts with behavioral health and nutrition support.
That plan changed. On April 21, 2026, CMS announced it would not move forward with the BALANCE Model in Medicare. BALANCE launched only for Medicaid, on May 1, 2026 (running through 2031); there is no Medicare BALANCE program. Instead of handing coverage to BALANCE, CMS extended the Medicare GLP-1 Bridge itself — it now runs through December 31, 2027 rather than ending in 2026, making it an 18-month demonstration.
What this means for you: your $50/month Bridge coverage is locked in through the end of 2027 — longer than originally scheduled. CMS has not yet finalized what happens after December 31, 2027, so treat post-2027 coverage as undecided rather than guaranteed.
Does Medicare Cover Wegovy or Zepbound for Weight Loss in 2026?
Yes — starting July 1, 2026, Medicare Part D covers both Wegovy (semaglutide) and Zepbound (tirzepatide) for weight loss under the obesity indication. This is the first time Medicare has covered GLP-1 medications prescribed specifically for chronic weight management, ending a two-decade prohibition under the Social Security Act.
Coverage runs through the Medicare GLP-1 Bridge program at a capped patient cost of$50/month from July 1, 2026 through December 31, 2027 (CMS extended the original 2026 end date). To qualify, Part D enrollees need documented BMI ≥ 30 (or BMI ≥ 27 with a qualifying comorbidity such as hypertension, dyslipidemia, or sleep apnea) and a prescription from a Medicare-enrolled provider. Ozempic and Mounjaro remain covered under their existing type 2 diabetes indications and are not part of this weight-loss-specific expansion.
What Happens After the Medicare GLP-1 Bridge Program Ends?
The Bridge now runs through December 31, 2027. CMS decided not to launch its companion BALANCE Model in Medicare, so what follows the Bridge after 2027 has not yet been determined.
The Bridge was originally scheduled to end December 31, 2026 and hand off to a permanent framework called the BALANCE Model. That did not happen the way it was first announced.13
What actually changed
- The Bridge was extended. Rather than ending in 2026, CMS extended the Medicare GLP-1 Bridge through December 31, 2027 — an 18-month demonstration at the same $50/month cost.
- BALANCE went to Medicaid, not Medicare. On April 21, 2026 CMS announced it would not implement the BALANCE Model in Medicare. BALANCE launched only for Medicaid on May 1, 2026, running through 2031.14
- Post-2027 is undecided. Because there is no Medicare BALANCE program to hand off to, what happens to Medicare GLP-1 coverage after the Bridge ends on December 31, 2027 has not been finalized. Watch for CMS guidance during the 2027 plan year.
What this means for your coverage
If you qualify and enroll now, your $50/month Bridge coverage is in place through December 31, 2027 — well over a year of locked-in pricing. Don't count on automatic coverage after that date until CMS publishes its post-Bridge plan.15
How Does Medicare GLP-1 Cost Compare to Other Coverage Options?
Medicare Bridge is the cheapest option at $50/month, compared to $150-$300/month with commercial insurance, $349/month via LillyDirect self-pay, or $998-$1,349/month at retail without any coverage.
To understand just how significant the Bridge program pricing is, here is a side-by-side comparison of what you would pay for GLP-1 weight loss medication under different coverage scenarios.
| Scenario | Monthly Cost | 6-Month Total | Annual Total |
|---|---|---|---|
| Medicare Bridge Program | $50 | $300 | $600 |
| Commercial Insurance (Good) | $25 – $75 | $150 – $450 | $300 – $900 |
| Commercial Insurance (Typical) | $150 – $300 | $900 – $1,800 | $1,800 – $3,600 |
| Manufacturer Savings Card | $0 – $150 | $0 – $900 | $0 – $1,800 |
| Compounded (Cash Pay) | $149 – $499 | $894 – $2,994 | $1,788 – $5,988 |
| Brand-Name (No Insurance) | $900 – $1,350 | $5,400 – $8,100 | $10,800 – $16,200 |
The Bridge program is unambiguously the lowest-cost option for Medicare beneficiaries. Even compared to the best commercial insurance plans, $50/month is competitive. And compared to cash pay — where many seniors have been spending $1,000+ per month — the savings are life-changing.
Note that manufacturer savings cards are generally not available to Medicare beneficiaries. Federal anti-kickback statutes prohibit manufacturers from subsidizing Medicare copays in most circumstances.16 The Bridge program effectively replaces what savings cards do for commercially insured patients.
How Do You Get Your First $50 Fill Now That the Program Is Live?
The Bridge is live — verify your Part D enrollment, get your BMI and any qualifying conditions documented at a doctor visit, and have your prescriber submit the Bridge prior authorization. Clean submissions approve in 5-14 days and you fill at the pharmacy at $50.
The Bridge program launched July 1, 2026 and is dispensing now. Here are the concrete steps to go from zero to your first $50 fill.
Verify Your Part D Coverage
Do this weekLog in to Medicare.gov or call 1-800-MEDICARE to confirm you have Part D or MA-PD coverage for 2026. If you don't, you may need to enroll during a Special Enrollment Period — talk to a Medicare counselor through your State Health Insurance Assistance Program (SHIP).
Get Your BMI Documented
This monthSchedule a visit with your primary care doctor. Have your BMI recorded and any weight-related conditions (diabetes, hypertension, sleep apnea, etc.) documented in your medical record. This documentation is essential for prior authorization.
Discuss GLP-1 Medication with Your Doctor
April – MayTalk to your doctor about whether Wegovy or Zepbound is appropriate for you. Discuss your medical history, current medications, and any contraindications. Your doctor should be preparing to submit prior authorization in late May or June.
Ask Your Plan About Bridge Program Logistics
May – JuneCall the member services number on your Part D plan card. Ask: (1) Is the Bridge program already in your formulary system? (2) What is the prior authorization process? (3) Which pharmacies can fill the prescription? (4) Is mail-order available?
Do Not Start Compounded GLP-1s as a Stopgap
ImportantSome patients are tempted to start on compounded semaglutide while waiting for July 1. Be cautious: compounded products are not FDA-approved, the FDA has issued warnings to 50+ compounders, and transitioning from a compounded dose to a brand-name dose requires medical supervision.
Can't Wait Until July?
If you need to start GLP-1 medication now and cannot wait for the Bridge program, we have independently reviewed 32 telehealth providers on cost, safety, and legitimacy. Some accept Medicare for off-label prescriptions, and others offer competitive cash-pay pricing.
See Provider RankingsFrequently Asked Questions
Done reading the policy?
See programs that accept Medicare or fit the $50/mo Bridge plan
The Bridge is live at $50/mo for qualifying enrollees. If you're in the eligibility gap — or your PA is still processing — our 2-minute quiz matches you with cash-pay programs at Medicare-comparable pricing, most under $150/mo.
When exactly does Medicare GLP-1 coverage start?
Do I need to switch Medicare plans to get coverage?
Will my doctor need to prescribe it specifically for obesity?
I already take Ozempic for diabetes. Does this change anything?
What happens after December 2026 when the Bridge program ends?
Can I get GLP-1 coverage through Medicare if I am under 65?
Will Medicare cover the cost of doctor visits related to GLP-1 prescriptions?
What if my BMI is below 27?
Are there quantity limits on how much medication I can get?
What if I experience side effects? Can I switch between Wegovy and Zepbound?
I live in a rural area. Can I use mail-order pharmacy?
Will the Bridge program affect my Part D premiums?
Sources & References
- CMS.gov. "Medicare GLP-1 Bridge" — official program page (eligibility, covered drugs, $50 copay, dates). cms.gov/medicare/coverage/prescription-drug-coverage/medicare-glp-1-bridge
- Kaiser Family Foundation (KFF). "What to Know About the BALANCE Model for GLP-1s in Medicare and Medicaid and the Medicare GLP-1 Bridge." Confirms the Bridge extension through Dec 31, 2027 and that BALANCE was not implemented in Medicare. kff.org
- U.S. Congress. TREAT (Treat and Reduce Obesity) Act of 2025. Included in the Bipartisan Budget Agreement, signed December 2025.
- CMS Office of the Actuary. "Estimated Eligible Population for the Medicare Anti-Obesity Medication Bridge Program." April 2026.
- CMS Final Rule: Medicare Program; Contract Year 2027 Policy and Technical Changes to the Medicare Advantage Program, Medicare Prescription Drug Benefit Program, and Medicare Cost Plan Program. Federal Register, April 2026.
- CMS Bridge Program Guidance Memo to Part D Plan Sponsors. "Implementation of the GLP-1 Bridge Program Cost-Sharing Requirements." February 2026.
- Kaiser Family Foundation. "Medicare GLP-1 Coverage: What We Know About Manufacturer Rebates." April 2026.
- FDA. Approved Drug Products: Ozempic (semaglutide) labeling — indicated for type 2 diabetes mellitus, not obesity.
- CMS Bridge Program Eligibility Criteria, Final Rule Section 423.2036(b). April 2026.
- CMS Guidance: "Part D Plan Sponsor Participation Requirements for the Bridge Program." All PDPs and MA-PDs must participate. February 2026.
- CMS Bridge Program Prescriber Standards, Final Rule Section 423.2036(c). April 2026.
- CMS Bridge Program Prior Authorization Guidance. "Streamlined Utilization Management for Anti-Obesity Medications." April 2026.
- CMS FAQ: "What to Expect During the First Months of the Bridge Program." April 2026.
- CMS Innovation Center. "The BALANCE Model: Beneficiary Access to Leveraged Anti-obesity and Nutrition Care for Equity." Model overview, March 2025.
- CMS Innovation Center. "BALANCE Model Value-Based Contracting Framework." Draft guidance, January 2026.
- CMS Bridge-to-BALANCE Transition Guidance Memo. "Continuity of Coverage for Anti-Obesity Medications." February 2026.
- OIG Advisory Opinion 2026-03: "Application of the Anti-Kickback Statute to Medicare Part D Anti-Obesity Medication Cost-Sharing."
Stay Updated on Medicare GLP-1 Coverage
The Bridge program details are still being finalized. We update this guide as CMS releases new guidance. Bookmark this page and check back for the latest information.